x

Cardio.Force Service

The Cardio.Force Service offers a non-invasive in vitro assay to measure true contractility of human cardiac myocytes with exceptional accuracy under physiological mechanical boundary conditions. The standard assay service is based on Ncardia’s proprietary Cor.4CE® system, and uses monolayers of Cor.4U® human cardiomyocytes. In a customized assay format also vCor.4U® or co-cultures of the cardiomyocytes with hiPSC-derived FibroCor.4U® cardiac fibroblasts can be applied.

The combination of Cor.4U® with the Cor.4CE® system is the first in vitro assay setup to measure true contractile force of iPSC-derived cardiomyocytes in a system compatible with medium throughput. The system provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes. 

 

Workflow

Service data

Service specifications

Cell type

iPSC-derived Cor.4U® cardiomyocytes

Species

Human

Service type

Biomechanical analysis 

Format

8 wells (on 24 well plate)

Time points

5-15 minutes after compound incubation

Compound concentrations*

0.001 µM – 10 µM (in 5 logarithmic steps) in medium + 0.1 %DMSO

 

Positive control

 Isoprenaline 0.001 µM – 0.1 µM; Verapamil 0.1 µM – 1 µM (in duplicates)

Vehicle control

 0.1% DMSO (in duplicates)

End-points

Highest dose - (optional washout)

Timelines

 7 weeks for up to 5 compounds (in quadruplicates)

Delivery

A study protocol will be agreed before study initiation. Results will be presented in a final study report.

* Suggested concentrations, to be agreed with client